Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $551.8 million.

  • Syndax Pharmaceuticals' Liabilities and Shareholders Equity rose 29.59% to $551.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 22.09%. This contributed to the annual value of $724.8 million for FY2024, which is 18.26% up from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Liabilities and Shareholders Equity stood at $551.8 million, which was down 7.44% from $596.1 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Liabilities and Shareholders Equity peaked at $724.8 million during Q4 2024, and registered a low of $239.5 million during Q3 2021.
  • For the 3-year period, Syndax Pharmaceuticals' Liabilities and Shareholders Equity averaged around $533.0 million, with its median value being $543.0 million (2024).
  • Data for Syndax Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY spiked of 165.96% (in 2021) over the last 5 years.
  • Syndax Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $449.7 million in 2021, then rose by 10.58% to $497.2 million in 2022, then increased by 23.26% to $612.9 million in 2023, then climbed by 18.26% to $724.8 million in 2024, then rose by 29.59% to $551.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $551.8 million in Q3 2025, compared to $596.1 million in Q2 2025 and $640.7 million in Q1 2025.